Previous 10 | Next 10 |
Drew Angerer/Getty Images News Agenus ([[AGEN]] -2.2%) has received a $200M upfront payment from Bristol-Myers Squibb ([[BMY]] -1.0%) as part of the closing of a license agreement for Agenus' bispecific antibody AGEN1777. AGEN1777, in late preclinical development, is designed to tar...
LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, t...
Agenus Inc. (AGEN) recently signed a collaboration agreement with Bristol-Myers Squibb (BMY) that has helped spark a large rally in the stock. The deal marks six active collaborations, providing the immuno-oncology concern with more shots on goal than just about any other clinical-sta...
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennife...
Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were up by a healthy 9.98% as of 11:08 a.m. EDT Thursday morning. The biotech's stock is rising today in response to the Food and Drug Administration's acceptance of the company's Biologics License Application (BLA)...
The U.S. FDA has accepted Agenus' (AGEN) Biologics License Application ((BLA)) for balstilimab for the treatment of a form of cervical cancer, and has granted "priority review" status to the submission.Under the Prescription Drug User Fee Act ((PDUFA)), the FDA has s...
3 Meme Penny Stocks For Your June Watchlist Meme penny stocks are here to stay. While it began as more or less of a joke, these small-caps have become extremely popular among all types of investors. But before we get into what they are, let’s talk about penny stocks . When in...
Shares of Agenus (NASDAQ: AGEN) were jumping 8.2% as of 11:24 a.m. EDT on Tuesday. The only news related to the company was VBI Vaccines ' (NASDAQ: VBIV) announcement that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for cancer vaccine candidate...
LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonst...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...